Pilot study on B2A shows comparable results to ICBG in lumbar spine fusion .
This report has been verified
by one or more authors of the
original publication.
Twelve-month results of a multicenter, blinded, pilot study of a novel peptide (B2A) in promoting lumbar spine fusion
J Neurosurg Spine. 2015 Apr;22(4):358-66.24 patients were included in this blinded, pilot, randomized clinical trial to evaluate a novel synthetic peptide, B2A, combined with ceramic granules and local bone autograft. Patients were randomized into one of three groups; either B2A at differing concentrations (750 or 150) combined with ceramic granules and local bone autograft at, or to iliac crest bone grafting. The results of this trial over a 12-month postoperative follow-up period indicated that patients in all three groups demonstrated similar rates of radiographic fusion and improvements in pain and disability. Additional clinical trials that utilize larger patient populations are needed before conclusions can be made regarding the use of B2A in this patient population.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
